-
Developing Effective Therapeutics for Difficult-to-Treat CancerseBookRecent years have introduced a variety of novel, targeted therapies for both hematopoietic and solid tumors. This includes monoclonal antibody therapies, CAR-T cells, bispecific antibodies, vaccines, and combination immunotherapies based on checkpoint blockade. Despite these therapeutic advances, some cancers remain extremely difficult to treat. In this eBook, we highlight some hard-to-treat cancer types including breast cancer, pancreatic cancer, and cervical cancer, and recent research into the development of therapies to advance treatment of these cancers. This includes biomarker identification in breast cancer and the development of CAR-T cells to treat glioma.
-
White Paper: Multiplex Cyclic Immunofluorescence WorkflowWhitepaperMultiplex immunohistochemistry (IHC) technologies are powerful tools to visualize multiple markers in the same tissue sample. These techniques, which include tyramide signal amplification and cyclic immunofluorescence, help scientists understand the cells that make up a tissue, what markers they express, their spatial distribution, and their potential interactions with one another. These methods depend on antibodies that are specific to the target, produce a clean signal, and have low background.
-
Cell Lysate Protocols eBookeBookThis eBook is a comprehensive resource for cell lysate preparation. It covers cell lysis using RIPA and NETN, as well as specific protocols for nuclear extract preparation and immunoprecipitation.
-
Drugs of Abuse Pairing GuideeBookAt Fortis Life Sciences®, we understand the importance of accurate and reliable rapid diagnostic tests for detecting drugs of abuse. That's why we are a global supplier of matched pairs of drug test reagents for use in lateral flow formats. Accelerate your development timeline by referencing this pairing guide for the selection of compatible drug test reagents.
-
VHH Antibodies: Novel Engineering Strategies Beget Diverse ApplicationsWhitepaperSingle-domain antibodies, also known as VHH, are a monomeric variable antibody domain. In research, therapeutic, and diagnostic applications, these single-domain antibodies have advantages over conventional antibodies. Applications of VHH include multiplex imaging, as a component of cell therapies or as a therapeutic modality themselves, and immunoassays for diagnostic and environmental monitoring assays.